Abstract

The aim of this open clinical trial was to evaluate the clinical efficacy of fusafungine (Bioparox Servier) in patients with upper respiratory infections. Patients and method: Twenty-one consecutive patients with upper respiratory tract infections were treated with fusafungine administered locally in four daily doses over seven days. The patients were volunteers and gave informed consent to participation in the clinical trial. Results: Good or very good results of treatment were observed in more than 60% of the patients. Fusafungine may be used as an effective alternative or an adjuvant to systemic antibiotic treatment in upper respiratory infections. 

Keywords: fusafungine, clinical efficacy, upper respiratory infections